A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

NCT06586957 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

150

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor
Advanced Solid Tumor
Solid Tumor, Adult
Metastatic Tumor
Ovarian Cancer
Ovarian Neoplasms
Ovarian Carcinoma
Metastatic Ovarian Carcinoma
Endometrial Neoplasms
Endometrial Diseases
Metastatic Endometrial Cancer
Triple Negative Breast Cancer
Metastatic Endometrial Carcinoma
Advanced Endometrial Carcinoma
Advanced Ovarian Carcinoma
Gastric Cancer
Advanced Gastric Carcinoma
Metastatic Gastric Cancer
Metastatic Gastric Carcinoma
Small Cell Lung Cancer
Small Cell Lung Carcinoma
Triple Negative Breast Neoplasms
Platinum-resistant Ovarian Cancer
Platinum-refractory Ovarian Carcinoma
CCNE1 Amplification
Hormone Receptor Negative Breast Carcinoma
Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Progesterone-receptor-positive Breast Cancer

Interventions

DRUG: NKT3964

Sponsor

NiKang Therapeutics, Inc.